This Q4 2008 Switzerland Pharmaceuticals and Healthcare Report Provides Independent Forecasts and Competitive Intelligence on the Industry

DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/a3317d/switzerland_pharma) has announced the addition of the "Switzerland Pharmaceuticals and Healthcare Report Q4 2008" report to their offering.

“Switzerland Pharmaceuticals and Healthcare Report Q4 2008”

The Switzerland Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Switzerland's pharmaceuticals and healthcare industry.

Despite the modest size of its population, the value of the Swiss pharmaceutical market reached US4.74bn in 2007, with the growth rate outperforming the European average for the year. Key driver of this growth has been the launch of innovative products, with the country's preference and acceptance for novel treatments resulting in the patented segment accounting for over two-thirds of the total market.

In the first half of the forecast period, the overall market growth will be steady, but unspectacular. The last two years of the period will witness negative growth, with the value forecast to reach just US5.17bn, as generic medicines continue to gain popularity. Consequently, in our new Business Environment Rankings for Q408, Switzerland has fallen from first – out of the eight key Western European markets – to second. The pole position has been relinquished to Germany, which is supported by strong growth of its prescription market and an increase in Value-Added Tax (VAT) medicines. Globally, however, Switzerland remains one of the best pharmaceutical markets in which to do business, being ranked third out of the 61 pharmaceutical markets surveyed , behind only the US and Germany. Local pharmaceutical powerhouses, led by Novartis and Roche, continue to show much dynamism in terms of recent activities.

In the meantime, Roche is looking for further expansion opportunities in the Americas region, with a particular focus on Brazil, mainly in oncology, inflammatory diseases, virology and central nervous system diseases. This shift in geographical focus shortly follows the company's decision to suspend research into new HIV/AIDS treatments, as none of its current candidate treatments represent significant improvements on existing therapies. Instead, Roche is stepping up its efforts in virology with research into hepatitis C virus (HCV) treatments – the leading cause of complications and mortality in HIV/AIDS patients.

Key Topics Covered:
Executive Summary
-Pharmaceutical Business Environment Ratings
-Limits of Potential Returns
-Risks to Realisation of Returns
-Market Summary
-Regulatory Regime
-Recent Approvals
-Intellectual Property Developments
-Pricing Regime
-Recent Pricing System Developments
-Reimbursement Regime
-Industry Developments
-Epidemiology
-Healthcare Insurance
-Healthcare Sector Financing
-Pharmaceutical Sector
-Company Developments
-Research and Development Sector
-Biotechnology Sector
-Industry Forecast Scenario
-Overall Market Forecast
-Key Growth Factors - Industry
-Key Growth Factors - Macroeconomic
-Prescription Market Forecasts
-OTC Market Forecast
-Patented Market Forecasts
-Generics Market Forecasts
-Export/Import Forecasts
-Other Healthcare Forecasts
-Medical Devices
-Key Risks to BMI's Forecast Scenario
-Competitive Landscape
-Company Profiles
-BMI Forecast Modelling
-How We Generate our Pharmaceutical Industry Forecasts
-Pharmaceutical Business Environment Ratings Methodology
-Ratings Overview
-Weighting

Companies Mentioned:
-GlaxoSmithKline (GSK)
-Pfizer
-Sanofi-Aventis
-Merck & Co
-Indigenous Manufacturers
-Novartis
-Roche
-Serono (Merck-Serono)

For more information visit http://www.researchandmarkets.com/research/a3317d/switzerland_pharma